Assoprol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Assoprol

What is Assoprol? (Overview)

Property Description
Active Ingredient Omeprazole
Form Delayed-Release Capsule or Tablet
Pharmacological Class Proton Pump Inhibitor (PPI)
General Purpose Strong, long-lasting acid suppression
Origin Synthetic/Chemical Drug

What Type of Medicine is Assoprol?

Assoprol is a brand name for a medication containing the active ingredient omeprazole. It belongs to a class of drugs known as Proton Pump Inhibitors (PPIs). This type of medication is used to reduce the amount of acid produced in the stomach. Omeprazole is a single-ingredient drug, meaning its primary therapeutic effects are derived from this one active component.

Omeprazole is used to decrease gastric acid levels, playing a role in the management of various acid-related conditions. The medication is designed to reduce the source of acid irritation directly. Assoprol is a chemically synthesized drug and, depending on regional regulations, may be available as an over-the-counter (OTC) medication for accessible acid management.


Composition and General Purpose

Assoprol is intended for oral administration and is typically manufactured as a delayed-release capsule or tablet. The active ingredient, omeprazole, is formulated with an enteric coating. This coating is designed to protect the medication from being broken down by stomach acid immediately upon ingestion.

This protective layer allows the medicine to pass through the stomach and dissolve in the small intestine, where it can be absorbed into the system. The primary purpose of Assoprol is to provide consistent acid suppression. By inhibiting the acid pumps in the stomach lining, the medication maintains a low-acid environment. This reduction in acidity is intended to support the recovery of tissues affected by acid reflux and to manage symptoms in scenarios such as frequent heartburn.

Regulatory References

  1. Omeprazole
  2. Proton Pump Inhibitor (PPI)
  3. MedlinePlus Drug Information: Omeprazole
  4. enteric coating

What side effects are possible with Assoprol?

Official Safety Profile of Assoprol (Omeprazole)

The official safety documentation for Assoprol is organized into frequency-based categories that describe the likelihood of experiencing documented adverse reactions. These effects are classified according to specific body systems or System-Organ Classes (SOCs).


Frequency-Classified Adverse Reactions

Classification Examples of Documented Reactions
Common (1 in 10 to 1 in 100 people) Headache, flatulence, abdominal pain, diarrhea, constipation, nausea, and vomiting.
Uncommon (1 in 100 to 1 in 1,000 people) Insomnia, dizziness, paresthesia, somnolence, increased liver enzymes, rash, pruritus, and peripheral edema.
Rare (1 in 1,000 to 1 in 10,000 people) Hypersensitivity reactions (e.g., fever, angioedema), blood disorders (leukopenia, thrombocytopenia), confusion, depression, taste disturbance, and hepatitis.

Serious Adverse Reactions and Constraints

Regulatory documents highlight serious adverse reactions that, while rare, are clinically significant. These include severe cutaneous adverse reactions (such as Stevens-Johnson syndrome), anaphylactic shock, hepatic failure, and specific blood dyscrasias like agranulocytosis.

Time-Related Safety Patterns are also noted: Prolonged use of Assoprol (typically over one year) has been associated with risks such as osteoporosis-related bone fractures of the hip, wrist, or spine, and Hypomagnesemia (low serum magnesium). Furthermore, use of the medicine may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD) and can interfere with specific laboratory tests for neuroendocrine tumors by elevating Chromogranin A (CgA) levels.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Assoprol (Omeprazole) describes overexposure scenarios where symptoms are generally transient and represent an intensification of expected adverse reactions.

Manifestation Category Documented Official Findings
Gastrointestinal & General Nausea, vomiting, abdominal pain, diarrhea, flatulence, headache, somnolence, and dry mouth.
Neurological & Cardiovascular Confusion, dizziness, blurred vision, and tachycardia (rapid heart rate).

Severe Manifestations and Patient Risk Severe clinical outcomes are considered rare. However, the regulatory label notes that more pronounced Central Nervous System (CNS) effects are documented, particularly in severely ill patients. These effects include reversible confusional states, agitation, depression, and hallucinations.

Emergency Action Mandate Seek immediate medical attention or contact a Poison Control Center upon suspicion of overdose. There is no specific antidote known for Omeprazole. Overdose management is officially defined as symptomatic and supportive treatment, which requires the implementation of appropriate monitoring and clinical management of the patient's condition.

The regulatory profile strictly mandates urgent medical intervention for all overexposure events due to the documented potential for severe CNS manifestations and the absence of a specific counteracting agent.

Therapeutic Uses of Assoprol

Main Uses and Therapeutic Areas

Assoprol is a medication primarily used to manage conditions related to excessive gastric acid production. By regulating the acid levels in the stomach, it assists in the healing of the digestive mucosa and provides relief from symptoms associated with acid-related disorders.

Treatment of Acid-Reflux Conditions

Assoprol is commonly indicated for the treatment of gastroesophageal reflux disease (GERD). This condition occurs when stomach acid flows back into the esophagus, causing irritation and inflammation. The medication helps to:

  • Reduce the symptoms of acid regurgitation and heartburn.
  • Facilitate the healing of erosive esophagitis, which is the physical damage to the lining of the esophagus caused by acid exposure.
  • Provide long-term maintenance to prevent the recurrence of esophageal inflammation.

Management of Peptic Ulcers

Assoprol is used in the treatment and prevention of ulcers located in the stomach (gastric ulcers) and the upper part of the small intestine (duodenal ulcers). Its role in ulcer management includes:

  • Active Ulcer Healing: Promoting the repair of the gastric or duodenal lining by maintaining a less acidic environment.
  • Prevention of Recurrence: Reducing the risk of ulcers returning in patients with a history of chronic ulcer disease.
  • NSAID-Associated Ulcers: Assisting in the healing and prevention of ulcers that may develop as a side effect of long-term use of non-steroidal anti-inflammatory drugs (NSAIDs).

Eradication of Helicobacter pylori

In cases where peptic ulcers are caused by an infection of the bacterium Helicobacter pylori, Assoprol is used as part of a combination therapy. When used alongside specific antibiotics, it creates an environment that allows the antibiotics to work more effectively to eliminate the infection, thereby allowing the ulcer to heal.

Hypersecretory Conditions

Assoprol is also indicated for rare pathological conditions where the stomach produces abnormally high amounts of acid, such as Zollinger-Ellison syndrome. In these instances, the medication helps manage the consistent overproduction of acid to prevent severe complications in the digestive tract.

Benefits of Treatment

The primary benefit of Assoprol therapy is the restoration of the balance of acid in the digestive system. By suppressing acid secretion, the medication allows damaged tissues in the stomach and esophagus time to recover. Patients typically experience a significant reduction in the discomfort and pain associated with chronic acid exposure, contributing to an improvement in overall digestive health.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

The eligibility for Assoprol (Omeprazole) is strictly governed by regulatory documentation, which outlines specific populations for permitted use and absolute contraindications.

Classification Eligibility Rules as Per Label Restriction Basis
Populations Allowed Adults (18+); Pediatric patients (1 to 16 years of age) for symptomatic GERD and Erosive Esophagitis. Children over 4 years for H. pylori eradication. Age and established safety/efficacy profiles.
Populations Contraindicated Patients with known hypersensitivity to omeprazole, substituted benzimidazoles, or any component of the formulation. Patients receiving nelfinavir or rilpivirine. Allergic history; Critical drug-drug interaction risk.

Age-Related Eligibility: Safety and effectiveness are not established for infants younger than 1 year of age.

Condition-Specific Restrictions: Use requires caution in patients with severely impaired hepatic function. For pregnancy, use is restricted and generally not recommended unless the potential benefit outweighs the risk. During lactation, the medicine is secreted into breast milk, requiring a decision to discontinue nursing or discontinue the medicine.

What should I know about interactions with other medicines?

The official interaction profile for Assoprol (Omeprazole) is structured around two key pharmacokinetic effects: the inhibition of the CYP2C19 enzyme and the product's action of significantly increasing gastric pH. Regulatory documents define interactions based on their effect on co-administered substances.

Category Official Regulatory Statement
Formal Contraindications Co-administration is formally contraindicated with the antiretrovirals Nelfinavir and Rilpivirine-containing products.
Exposure Alteration Assoprol reduces the plasma concentration of medicines requiring an acidic environment for absorption, such as Atazanavir and the antifungals Ketoconazole and Itraconazole.
Metabolic Effects Assoprol may prolong the elimination and increase the plasma concentration of medicines metabolized by CYP2 C19, including Warfarin, Phenytoin, and Diazepam.
Platelet Activity Risk Assoprol is documented to diminish the anti-platelet activity of Clopidogrel, especially at the 80 mg dose, due to CYP2 C19 inhibition.
Timing Rules Assoprol must be temporarily stopped (e.g., at least 14 days) before measuring plasma Chromogranin A ( CgA) levels for specific diagnostic purposes.
Herbal/Supplement Co-administration with the herbal product St. John's Wort and the antibiotic Rifampin is discouraged as they may reduce Omeprazole's plasma concentrations.

These documented effects lead to formal restrictions and cautions regarding concurrent use. The interaction profile necessitates that the effects on plasma exposure are monitored when Assoprol is used with affected products, particularly in patients with hepatic impairment where clearance may be slower. The regulatory classification ensures that the severity and nature of the interaction are clearly defined.

Mechanism of Action

Irreversible Covalent Inhibition of the Proton Pump

The mechanism of action is defined by a specific, irreversible inhibition of the H^+/K^+-ATPase enzyme, commonly known as the Proton Pump, located in the gastric parietal cells. Assoprol acts as a prodrug that is selectively concentrated in the highly acidic environment of the parietal cell canaliculi. This acidity catalyzes the conversion of the inactive Omeprazole into its active sulfenamide metabolite. The active form then forms a stable covalent disulfide bond with specific cysteine residues on the Proton Pump structure, directly and permanently halting the transport of hydrogen ions ( H^+). This molecular cascade results in the suppression of the acid secretion pathway.


⏳ Sustained Effect Determined by Enzyme Turnover

Because the drug's binding to the pump is irreversible, the resulting acid suppression is maintained until the parietal cell synthesizes and inserts a new, functional pump into its membrane. The duration of this physiological effect is therefore governed by the natural rate of enzyme turnover—the body's protein replacement cycle—rather than the time the drug stays in the bloodstream. This leads to a sustained elevation of the intragastric pH level.

Dosage and Administration Information

How to Use Assoprol

Assoprol (Omeprazole) is primarily administered via the oral route, typically as a delayed-release capsule or tablet. For patients temporarily unable to take oral medication, an alternative route is available as an intravenous (IV) infusion, administered over a period of 20 to 30 minutes.


Standard Dosing and Frequency

For most acute acid-related conditions, the standard regimen involves taking 20 mg or 40 mg once daily. In the management of pathological hypersecretory conditions, dosing is individualized; total daily doses that exceed 80 mg must be formally divided and administered in multiple doses throughout the day. Treatment for acute conditions, such as erosive esophagitis, typically follows a defined course of 4 to 8 weeks, though maintenance therapy may extend up to 12 months.


Administration and Handling

Oral delayed-release forms must be taken before a meal, preferably in the morning. This timing is critical for the medicine to work as intended. Capsules must be swallowed whole with water and should not be chewed or crushed, as disrupting the protective enteric coating should be avoided. If swallowing the capsule whole is not feasible, the pellets inside may be mixed with a small amount of specified soft food, such as applesauce, and swallowed immediately.

Adjustments and Missed Dose

No dose adjustment is required for older adults or patients with renal impairment. However, dose reduction may be necessary for individuals with severe hepatic impairment due to reduced drug clearance. If a dose is missed, it should be taken as soon as possible, but patients must not take two doses at the same time to compensate for the missed one.

Recent Clinical Evidence

Research evidence / Overview of studies for Assoprol


Evidence for Healing and Preventing Relapse of Esophageal Damage (Erosive Esophagitis)

The research base for Assoprol (Omeprazole) was evaluated in conditions such as damage to the esophagus lining (erosive esophagitis) and primarily involves short-term Randomized Controlled Trials (RCTs) and longer-term studies. Research was conducted during periods of increased symptom activity. Researchers monitored the initial healing process and examined patterns related to recurrence. Outcomes measured included endoscopic healing status and patient-reported outcomes describing perceived discomfort related to reflux symptoms like heartburn.

Research also describes patterns where the measured healing outcomes varied depending on the extent of the initial damage. This evidence contributes to the broader understanding of symptom patterns. Information regarding the relationship between short-term healing measurements and very long-term esophageal health is limited in existing evidence.


Research Supporting the Management of Ulcers and Related Conditions

Assoprol was studied for its role in conditions involving both duodenal and gastric ulcers that form in the stomach and upper intestine. This research included systematic reviews and RCTs that explored short-term symptom changes. When Omeprazole is part of a combination regimen for research examining the bacterium Helicobacter pylori, research examined the achievement of bacterial clearance by the regimen and subsequently monitored patterns related to the recurrence of duodenal ulcers.


Long-Term Evidence and Durability of Response

For conditions like Zollinger-Ellison Syndrome, research relies on long-term prospective cohort studies. Researchers monitored acid output and findings show patterns related to sustained measurements in these specific populations. Research observed the need for continuous monitoring and adjustment of acid output measurements over the long term in some patients. There is limited information for long-term outcomes regarding managing the risk of relapse years after healing is observed.


Research Gaps and Areas of Uncertainty

Evidence quality varies across studies, and some early research in pediatric populations included designs where a direct comparison to a placebo was lacking. Comparative evidence is lacking for some of the newer treatment strategies compared to established alternative treatments. Certainty remains low regarding the very long-term effects of continuous, high-dose therapy beyond the observation periods currently reported in the literature.

Key Studies & References

  1. Drug treatment strategies for erosive esophagitis in adults: a narrative review

Frequently Asked Questions (FAQ)

Common questions about Assoprol (FAQ)


Q: What happens if I accidentally miss a dose of Assoprol?

Regulatory instructions for a missed dose state that it should be taken as soon as it is remembered. However, it is explicitly advised not to take two doses at the same time to compensate for the missed one.

Q: Is Assoprol generally considered for people with a history of kidney issues?

Official information indicates that a dose adjustment is generally not required for patients with renal impairment (kidney issues). However, there have been observations of a rare condition called acute interstitial nephritis (a type of kidney inflammation) in patients using this class of medicine. If this occurs, patients are advised to seek medical evaluation.

Q: Has Assoprol been studied in older adults or senior populations?

Yes, official regulatory documents, such as those from the FDA, include a specific section addressing the use of this medicine in older adult and geriatric populations.

Q: What are the differences between the various doses of Assoprol available?

Official documents define different dose strengths for distinct purposes, reflecting the need to address various medical conditions. This difference ensures the medication is used appropriately for its approved indications.

Q: What is the official purpose of Assoprol, according to the FDA documents?

The official documentation lists multiple approved uses. These include the treatment of symptoms related to gastroesophageal reflux disease (GERD), the healing of duodenal and gastric ulcers, and the long-term management of pathological hypersecretory conditions.

Q: Is Assoprol known to interact with alcohol?

The regulatory warning for the omeprazole-aspirin combination product addresses potential risks and advises consultation with a healthcare professional, particularly for individuals who consume three or more alcoholic drinks daily. Standard regulatory information may not provide general advice regarding alcohol consumption.

Q: Can Assoprol impact blood pressure readings?

Postmarketing reports—surveillance reports collected after the medicine is approved—have included descriptions of elevated blood pressure or hypertension as potential effects, although these are typically rare.

Q: Does Assoprol require any routine blood tests or monitoring?

Yes, regulatory guidance suggests monitoring is recommended for long-term use. This specifically involves checking for Hypomagnesemia (low magnesium levels) and monitoring for any interference with diagnostic investigations for certain neuroendocrine tumors.

Q: What is Assoprol actually used for besides the main thing everyone talks about?

In addition to common uses like treating GERD, the medicine is officially approved for conditions such as the healing of specific types of ulcers and the long-term treatment of complex conditions involving excessive stomach acid production.

Q: Is Assoprol a type of [Class of drug]?

Assoprol is categorized as a Proton Pump Inhibitor (PPI). This class of medicine works by targeting and inhibiting the specialized 'pumps' in the stomach that produce acid.

Q: Does Assoprol affect sleep patterns?

Official adverse reaction reports indicate that insomnia (difficulty sleeping) has been reported in clinical trials. Other sleep disturbances have also been described in postmarketing reports.

Q: How long after starting Assoprol should I expect to notice a change?

Official information on how the drug works indicates that the onset of the acid-reducing effect begins within one hour of taking a dose. However, the full, stable inhibitory effect typically takes about four days of repeated daily dosing to reach its maximum level.

Q: Is it common to feel [Vague symptom, e.g., tired or foggy] when taking Assoprol?

Adverse effects documented in clinical trials and postmarketing surveillance include feelings of fatigue (tiredness), dizziness, and asthenia (weakness). While these are documented, they are generally reported infrequently.

Q: Can Assoprol be taken with common over-the-counter pain relievers?

Regulatory information notes there is no known interaction with Acetaminophen (commonly known as Tylenol). However, specific warnings exist regarding the combined use of Assoprol with certain nonsteroidal anti-inflammatory drugs (NSAIDs) like Aspirin due to potential interaction risks.

Q: What are the most commonly reported side effects of Assoprol?

The most frequently reported side effects in controlled clinical trials are headache, abdominal pain, nausea, vomiting, diarrhea, and flatulence (gas).

Q: Is Assoprol safe for long-term use?

Regulatory warnings indicate that daily use for periods longer than one year may be associated with increased risks. These potential risks are reported to include bone fracture, specific infections, and possible deficiencies in Vitamin B-12 and magnesium.

Q: Is it normal if I don't feel anything in the first week of taking Assoprol?

The full stable acid-inhibiting effect typically takes about four days of consistent daily dosing to build up. Symptom relief may follow this timeline.

Q: Can Assoprol cause weight changes?

Weight increase has been listed in postmarketing reports as a very rare potential effect of the medicine.

Q: Is there a generic version of Assoprol available?

Yes, regulatory documents and official publications confirm that the medicine's active ingredient, Omeprazole, is widely available in generic versions.

Q: What should I do if a side effect of Assoprol feels annoying but not severe?

Official patient labeling typically recommends consulting a healthcare professional if non-severe symptoms develop or persist, or if the underlying condition worsens.

Q: Can Assoprol affect my ability to drive or operate machinery?

Because adverse effects such as dizziness, somnolence (drowsiness), or vertigo (a sensation of spinning) have been reported, caution is generally advised for tasks requiring full mental alertness, such as driving or operating heavy machinery.

Q: Do research studies show that Assoprol is effective for its intended use?

Yes, regulatory documents include detailed sections on controlled clinical studies which supported the approval of the drug by demonstrating its efficacy for various approved indications.

Q: Why is Assoprol not recommended for certain age groups?

Regulatory documents define specific approved uses and maximum durations for pediatric patients because the safety and efficacy are formally established only for these parameters. Use outside of these guidelines is not recommended.

Q: Are there any widely known contraindications for Assoprol?

Yes, formal contraindications are defined in regulatory labels. These include known hypersensitivity (severe allergic reaction) to the drug or its components, and concomitant use with specific antiretroviral medicines.

Q: Can taking Assoprol cause changes in mood or emotional state?

Mood-related effects such as occasional insomnia, agitation, depression, and reversible confusional states have been reported. These have been noted particularly in patients who were severely ill.

Q: Is Assoprol the same drug as the one used in [Another country name]?

Assoprol contains the active ingredient Omeprazole, which is the internationally recognized name for this compound. It is referenced in regulatory documents globally, including those from the EMA (Europe) and NIH (US).

Q: What does the official patient information leaflet say about Assoprol?

Official patient information typically provides crucial safety warnings, describes the most common side effects, and gives general guidance on when to seek immediate medical attention for serious symptoms.

Q: What are the requirements for being eligible to take Assoprol?

Eligibility is determined by having an approved medical condition (indication) for the medicine, as well as the absence of formal contraindications or specific warnings that would make use inappropriate for the patient, such as a known allergy to the drug.

Q: What kind of studies support the use of Assoprol for its main indication?

The drug's approval is supported by evidence from controlled clinical studies described in the regulatory files. These studies often involve trials that compare the drug to a placebo or to an active comparator to demonstrate its therapeutic effect.

Q: Does Assoprol have any effects on liver function?

Adverse reaction reports include mentions of elevated liver enzymes, and isolated, rare cases of hepatitis and hepatic failure. Regulatory documents advise that a dose reduction is recommended for patients who have severe hepatic impairment (serious liver damage).

Q: Is Assoprol safe for breastfeeding patients according to regulatory sources?

Official patient labeling advises consulting a healthcare professional before use if a patient is pregnant or breastfeeding to assess individual circumstances and guidance.

Q: What are the common signs of an allergic reaction to Assoprol?

Signs of a serious allergic reaction may include rash, blisters, skin reddening, angioedema (swelling, often of the face or throat), and trouble breathing. Any of these symptoms require immediate medical attention.

Q: Are there any specific activities to avoid while taking Assoprol?

Due to reports of dizziness, somnolence, or vertigo, caution is generally advised for activities that require full mental alertness, such as driving or operating heavy machinery.

Q: Is Assoprol listed on the World Health Organization's list of essential medicines?

Yes, Omeprazole (Assoprol) is included on the World Health Organization’s (WHO) Model List of Essential Medicines. This list contains medicines considered to be the most effective and safe to meet priority health care needs.

Q: Can Assoprol be stopped suddenly, or does it require gradual discontinuation?

Regulatory guidance suggests patients discuss with a healthcare provider the option of gradually stopping the medicine, as symptoms that were being managed may worsen or experience a 'rebound' if treatment is stopped suddenly.

How should Assoprol be stored and disposed of?

Storage Conditions

Assoprol (Omeprazole) must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). The medicine must be kept in its original container and protected from both light and moisture to safeguard the sensitive delayed-release formulation. If supplied in a bottle, the container must be kept tightly closed. It is mandatory to store Assoprol out of the reach of children.

Stability and Handling

If the capsule contents are mixed with liquid or soft food for administration, the resulting mixture must be swallowed immediately or within 30 minutes and must not be stored for later use. For some bottle formulations, a specific in-use period may apply after opening, provided the bottle remains tightly closed.

Disposal Instructions

Any unused or expired Assoprol must be disposed of according to local requirements. The medicine should not be thrown into wastewater or general household waste to protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Assoprol found in:

A-Z Index: